Lifeboat Foundation

Agree; this is our future.

Almost ten years ago, Freeman Dyson ventured a wild forecast:

“I predict that the domestication of biotechnology will dominate our lives during the next fifty years at least as much as the domestication of computers has dominated our lives during the previous fifty years.”

Continue reading “Why We Should Teach Kids to Code Biology, Not Just Software” »

Zika. Ebola. Dengue. Influenza. Chikungunya. These are but a few among the growing cadre of viruses that today pose serious health threats to U.S. troops, as well as to civilian populations in the United States and around the world. Vaccines exist for but a few of these infectious diseases. And since these viruses have an uncanny ability to mutate and morph as they reproduce inside their hosts, those few vaccines that do exist are quickly outdated, providing little protection against the latest viral strains. That’s why flu vaccine manufacturers, for example, must produce new versions annually, at enormous expense and with variable year-to-year efficacy.

Ideally, to outpace evolving pathogens, a therapy or a vaccine would adapt in real time, shape-shifting as fast as its targets do. To pursue that radical approach, DARPA today launched its INTERfering and Co-Evolving Prevention and Therapy (INTERCEPT) program.

“We need a new paradigm to stay ahead of these moving targets,” said Jim Gimlett, DARPA program manager. “With INTERCEPT, the goal is to develop viral therapies that are effective against a broad spectrum of viral strains, and that can co-evolve and outpace new strains.”

A common drug could hold the key to long life, in flies at least, according to research.

At low doses, lithium prolonged the life of fruit flies in lab experiments.

Scientists say the finding is “encouraging” and could eventually lead to new drugs to help people live longer and healthier lives.

The CRISPR/Cas9 gene-editing platform may need a little bit more tweaking before it can be used as an effective antiviral, reports a study published April 7 in Cell Reports. Researchers who used CRISPR/Cas9 to mutate HIV-1 within cellular DNA found that while single mutations can inhibit viral replication, some also led to unexpected resistance. The researchers believe targeting multiple viral DNA regions may be necessary for the potential antiviral aspect of CRISPR/Cas9 to be effective.

Upon entry into a cell, HIV’s RNA genome is converted into DNA and becomes entwined with the cellular DNA. From here, CRISPR/Cas9 can be programmed to target a DNA sequence and cleave viral DNA. The problem is that HIV is notoriously good at surviving and thriving with new mutations, so while many viruses are killed by the targeted approach, those that escape the CRISPR/Cas9 treatment become more difficult to target.

“When we sequence the viral RNA of escaped HIV, the surprise is that the majority of the mutations that the virus has are nicely aligned at the site where Cas9 cleaves the DNA, which immediately indicates that these mutations, instead of resulting from the errors of viral reverse transcriptase, are rather introduced by the cellular non-homologous end joining machinery when repairing the broken DNA,” says senior study author Chen Liang, Senior Investigator at the Lady Davis Institute at the Jewish General Hospital and the Associate Professor of Medicine at the McGill University AIDS Centre.

Nice

Recovering mobility after a stroke or an accident can take a lot of hard work. Now a team in Manchester is using virtual reality to help patients get moving again.

Marge Brown cannot help the tears welling up in her eyes as she watches her husband stroll on a treadmill through a virtual wood he can see on the giant video screen in front of him.

Continue reading “Virtual reality puts patients on the road to recovery” »

One million movies are stored in this vial of water.

30.03.16 — Public Release of Platforms Will Help Advance Collaborative Research in Neuroscience, Medicine, and Computing

The Human Brain Project (HBP) is pleased to announce the release of initial versions of its six Information and Communications Technology (ICT) Platforms to users outside the Project. These Platforms are designed to help the scientific community to accelerate progress in neuroscience, medicine, and computing.

The Platforms released today consist of prototype hardware, software tools, databases and programming interfaces, which will be refined and expanded in a collaborative approach with users, and integrated within the framework of a European Research Infrastructure. The public release of the Platforms represents the end of the Ramp-Up Phase of the HBP and the beginning of the Operational Phase.

Continue reading “Human Brain Project’s Research Platforms Released” »

We would also see a decrease in the hundreds of thousands of arthritis-induced knee and hip replacement surgeries every year.

Stem cells, human trials, regenerative medicine, yay!

Continue reading “A stem-cell repair system that can regenerate any kind of human tissue” »